首页> 外文期刊>Urology Annals >Comparison between the use of 99% ethanol and 3% polidocanol in percutaneous echoguided sclerotherapy treatment of simple renal cysts
【24h】

Comparison between the use of 99% ethanol and 3% polidocanol in percutaneous echoguided sclerotherapy treatment of simple renal cysts

机译:比较99%乙醇和3%polidocanol在经皮超声引导下硬化疗法治疗简单肾囊肿中的比较

获取原文
           

摘要

Aim: In this study, we compared and valued efficacy and safety of percutaneous echoguided sclerotherapy (PES) using 3% polidocanol with that using 99% ethanol in the treatment of patients with simple renal cysts. Materials and Methods: PES was performed for 65 simple renal cysts. Under ultrasonographic guidance the cyst was punctured using an 18 gauge needle. Sclerotherapy was performed with ethanol in 55% (36/65) of cases and with polidocanol in the remaining 45% (29/65). Patients were followed up with an ultrasound examination at 4 months, 8 months, and then at yearly intervals. A reduction of 50% or greater in cyst diameter was considered successful. Results: The median followup period for the ethanol and polidocanol groups was 24.6 and 22.8 months, respectively. The successful outcome ratio of the polidocanol group was significantly higher (90% vs. 61%, respectively) than the one of the ethanol group (P = 0.003). The partial regression of the ethanol and polidocanol groups were 6% versus 7%, respectively. The failure ratio of the polidocanol group was significantly lower (3% vs. 33%, respectively) than that of the ethanol group (P = 0.004). Neither infectious complications nor hyperthermia occurred in all treated cases. However, these methods are not completely free from symptoms. All these symptoms disappeared few hours after the procedure. Conclusions: Polidocanol is a safe and effective sclerosing agent for renal cysts, with superior clinical results than ethanol. Therefore, polidocanol can be an alternative to ethanol in sclerotherapy of renal cysts.
机译:目的:在本研究中,我们比较并评价了使用3%的多多酚醇和99%的乙醇经皮回声引导硬化疗法(PES)治疗单纯性肾囊肿的疗效和安全性。材料与方法:对65例单纯性肾囊肿行PES检查。在超声引导下,使用18号针头刺破囊肿。在55%(36/65)的病例中使用乙醇进行硬化治疗,在其余45%(29/65)的患者中使用多多酚进行硬化治疗。分别在4个月,8个月和随后的每年间隔对患者进行超声检查。囊肿直径减少50%或更大被认为是成功的。结果:乙醇组和多多酚组的中位随访期分别为24.6和22.8个月。多多酚醇组的成功结局比率显着高于乙醇组(P = 0.003)(分别为90%和61%)。乙醇组和多多酚醇组的部分回归分别为6%和7%。波多克多醇组的失败率显着低于乙醇组(分别为3%和33%)(P = 0.004)。所有治疗病例均未发生感染性并发症或高热。但是,这些方法并非完全没有症状。术后数小时所有这些症状消失。结论:聚多卡醇是一种安全有效的肾囊肿硬化剂,临床疗效优于乙醇。因此,在肾囊肿硬化治疗中,多多酚可以替代乙醇。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号